Do you recommend bevacizumab in platinum sensitive recurrences of epithelial ovarian cancer?

Bevacizumab was approved for use in combination with chemotherapy followed by continued bevacizumab maintenance in patients with platinum-sensitive recurrent ovarian cancer in December 2016. This approval was based on the findings of 2 studies, GOG-213 and the OCEANS trial. Both trials demonstrated an improvement in progression free survival (PFS) with the addition of bevacizumab. GOG-213 demonstrated a non-statistically significant 5 month improvement in overall survival (OS) in patients receiving bevacizumab. There are several considerations. Since bevacizumab has been used extensively in combination with chemotherapy in clinical trials of initial ovarian cancer therapy and is now approved by the FDA for use in combination with chemothera...